PTC Therapeutics (PTCT)

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 939
• Incorporated in 1998 
• Headquartered in Warren, New Jersey
• https://www.ptcbio.com

IPO : June 20, 2013

PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and proprietary small-molecule drugs for patients living with serious and life-threatening conditions, including genetic and neuromuscular disorders, cancer, and infectious diseases. Its approach includes post-transcriptional control, RNA biology, and gene expression modulation by small-molecules. The company has strategic alliances with AstraZeneca; Celgene Corporation; Cystic Fibrosis Foundation; Genzyme Corporation; Gilead; Muscular Dystrophy Association; Merck & Co., Inc.; Parent Project Muscular Dystrophy; Pfizer Inc.; Roche; Spinal Muscular Atrophy Foundation; and Wellcome Trust. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.

Address

100 Corporate Court
SOUTH PLAINFIELD, NJ 07080-2449
United States 

Website links www.ptcbio.com

Key stats and ratios

	Q1 (Mar '13)	2012
Net profit margin	-205.62%	-77.28%
Operating margin	-120.09%	-78.97%
EBITD margin	-	-71.01%
Return on average assets	-	-91.70%
Return on average equity	-	-
Employees	123